Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.7383
-0.0195 (-2.57%)
At close: Mar 28, 2025, 4:00 PM
0.7561
+0.0178 (2.41%)
After-hours: Mar 28, 2025, 7:41 PM EDT
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,613,557
Profits / Employee
-$1,950,180
Market Cap
137.40M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NKTR News
- 9 days ago - Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - PRNewsWire
- 17 days ago - Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 24 days ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 4 weeks ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata - PRNewsWire
- 4 weeks ago - Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus - PRNewsWire
- 4 weeks ago - Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th - PRNewsWire
- 6 weeks ago - Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis - PRNewsWire